Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in Transfusion-dependent Low/Int-1 Risk MDS and CMML
NCT01048034Phase 2Completed
- Sponsor
- Nordic MDS Group
- Start
- Jan 2010
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of azacitidine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Nordic MDS Group. Started Jan 2010; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01048034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01048034.